Jacobio Pharma, a Beijing clinical-stage biotech, raised $55 million in a C funding led by Qiming and Hillhouse. The company’s lead asset, a small molecule oncology drug, has started a US Phase I trial in patients with solid tumor cancers and has been approved to begin a similar trial in China. Jacobio said it has ten projects in development. It is focused on innovative drugs for unmet needs in China and abroad, especially for cancer, autoimmune and infectious diseases.
Source: China Biotoday
